Biologics are more effective at treating adult-onset Still’s disease (AOSD) than are glucocorticoids or conventional disease-modifying antirheumatic drugs (DMARDs), according to a new retrospective ...

Patients with rheumatoid arthritis (RA) whose symptoms improved after they started taking nonbiologic disease-modifying antirheumatic drugs (DMARDs) also demonstrated restored balance in their oral ...

Please provide your email address to receive an email when new articles are posted on . Maximizing the disease-modifying benefits of methotrexate is one of the core principles behind the 2021 American ...

About one-third of patients prefer in-hospital administration, particularly if they are older or already make frequent visits to the hospital. Most patients with rheumatoid arthritis (RA) would prefer ...

Please provide your email address to receive an email when new articles are posted on . Patients with RA who responded to DMARD therapy showed reduced microbiome levels of certain bacteria. DMARD ...

Still's disease is an unusual form of arthritis that, in children, is also called systemic juvenile idiopathic arthritis, but it can also develop in adults. Few rigorous studies have examined biologic ...

Using telemedicine to monitor patients with rheumatoid arthritis (RA) initiating disease-modifying antirheumatic drugs (DMARDs) was highly cost-effective and resulted in similar health outcomes ...

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

There’s no cure for rheumatoid arthritis (RA), but early treatment with disease-modifying antirheumatic drugs (DMARDs) may push symptoms into remission and slow disease progression. Treatment options ...

Since their first publication in 2010, the EULAR recommendations for the use of disease-modifying anti-rheumatic treatments (DMARDs) in people with RA have become a most important publication in the ...

Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway. Stimulation of this pathway would be a novel ...